Study study type
PathologyT1T0Patientssample sizesROB Results

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1)

versus nab-paclitaxel
nab-paclitaxel
FUTURE-SUPER_immunomodulatory subtype, 2024
  NCT04395989		RCTmBC - Triple negative (TNBC) - 1st Line (L1)camrelizumab plus famitinib plus nab-paclitaxelnab-paclitaxelfemales aged 18–70 years with an histologically confirmed, untreated metastatic or recurrent triple-negative breast cancer69 / 70some concern
 inconclusive
  • suggested 54 % decrease in progression or deaths (PFS)
the subtyping-based precision treatment showed significantly improved progression-free survival compared with standard chemotherapy in the first-line treatment of metastatic triple-negative breast cancer.

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus nab-paclitaxel
nab-paclitaxel
GeparNuevo, 2019
  NCT02685059		RCTes-BC - TNBC - NA - all populationdurvalumab followed by nab-paclitaxelplacebo followed by nab-paclitaxelPatients with previously untreated uni- or bilateral primary, non-metastatic invasive TNBC with a tumour of at least 2 cm (cT2-cT4a-d) treated as neoadjuvant88 / 86some concern
 suggested
  • suggested 76 % decrease in deaths (OS) (extension)
  • inconclusive 45 % increase in pCR (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons